-
2 weeks ago | 
ajmc.com | Brooke McCormick |Sheela Rao
On May 15, the FDA approved retifanlimab-dlwr (Zynyz; Incyte) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. It was also approved as a monotherapy for those whose disease has progressed or who are intolerant to platinum-based chemotherapy.
-
3 weeks ago | 
ajmc.com | Brooke McCormick |Ola Landgren
Ahead of this year's European Hematology Association (EHA) Congress in Milan, Ola Landgren, MD, PhD, chief of the myeloma division and leader of the experimental therapeutics program at Sylvester Comprehensive Cancer Center, and professor of medicine at the University of Miami, shares what he is most looking forward to at the meeting.
-
3 weeks ago | 
ajmc.com | Brooke McCormick
May was a productive month for the FDA, with multiple drug approvals spanning a range of therapeutic areas, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, and hemophilia A. The timeline below highlights 5 key dates last month when significant advancements were made across these and other disease states.
-
3 weeks ago | 
ajmc.com | Brooke McCormick
Inhaled corticosteroid (ICS) use is common in patients with bronchiectasis, including those for whom it is not currently recommended, and may be associated with a reduced frequency of exacerbations, according to a study published in Thorax.1 The researchers noted that ICS, which are anti-inflammatory and immunosuppressive drugs that inhibit the expression of various pro-inflammatory genes, have shown benefits in patients with eosinophilic airway diseases, such as asthma and eosinophilic...
-
3 weeks ago | 
ajmc.com | Brooke McCormick
May was a productive month for the FDA, with multiple drug approvals spanning a range of therapeutic areas, including chronic obstructive pulmonary disease (COPD), plaque psoriasis, and hemophilia A. The timeline below highlights 5 key dates last month when significant advancements were made across these and other disease states.
-
3 weeks ago | 
ajmc.com | Brooke McCormick |Brian M. Slomovitz
In the second part of an interview with The American Journal of Managed Care®, Brian Slomovitz, MD, an investigator on the phase 3 ROSELLA trial (NCT05257408), discusses how the combination of relacorilant plus nab-paclitaxel (Abraxane) compares with other available treatment options for patients with platinum-resistant ovarian cancer. He also underscores the importance of the ROSELLA trial's global scope.
-
3 weeks ago | 
ajmc.com | Brooke McCormick
Men’s Health Month highlights the importance of preventive care and healthy habits for men, with a renewed focus on prostate cancer awareness following former President Joe Biden’s recent diagnosis.1 Men’s Health Month is observed each June in the US to raise awareness among men, boys, and their families about the importance of preventive care, healthy lifestyle choices, and positive health attitudes.2 The observance began with the establishment of National Men’s Health Week, signed into law...
-
3 weeks ago | 
ajmc.com | Brooke McCormick |Brian M. Slomovitz
Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free survival and prolonged overall survival in patients with platinum-resistant ovarian cancer compared with nab-paclitaxel alone, according to results from the phase 3 ROSELLA trial (NCT05257408) shared Monday in a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
3 weeks ago | 
ajmc.com | Brooke McCormick
The prevalence of fair or poor health among occupational groups generally increased with the prevalence of high economic hardship, according to a study published last Thursday in the CDC’s Morbidity and Mortality Weekly Report, highlighting persistent gaps in worker health and employment sustainability.1 Economic hardship, defined as the inability to afford basic needs, such as food, clothing, and health care, adversely affects health.2Building on past findings, the researchers stressed that...
-
3 weeks ago | 
ajmc.com | Brooke McCormick
Oncology biosimilars may help alleviate some of the financial toxicity faced by both patients and health care systems due to cancer care, according to 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.
